Pharmacological advances in the treatment of nonalcoholic fatty liver diseases : focused on global results of randomized controlled trials
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of liver disease globally, and its prevalence is rapidly increasing. Nonalcoholic steatohepatitis (NASH), a progressive form of NAFLD, is characterized by hepatocellular injury, inflammation, and fibrosis. Patients with NASH or severe...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Korean Association for the Study of the Liver
2023-02-01
|
| Series: | Clinical and Molecular Hepatology |
| Subjects: | |
| Online Access: | http://e-cmh.org/upload/pdf/cmh-2022-0437.pdf |
| _version_ | 1797871538692685824 |
|---|---|
| author | Jihyun An Joo Hyun Sohn |
| author_facet | Jihyun An Joo Hyun Sohn |
| author_sort | Jihyun An |
| collection | DOAJ |
| description | Nonalcoholic fatty liver disease (NAFLD) is the most common cause of liver disease globally, and its prevalence is rapidly increasing. Nonalcoholic steatohepatitis (NASH), a progressive form of NAFLD, is characterized by hepatocellular injury, inflammation, and fibrosis. Patients with NASH or severe fibrosis should be treated according to international NAFLD guidelines. Currently, regulatory agencies have not approved any pharmaceutical treatment for NAFLD. Vitamin E and pioglitazone are efficacious for NASH resolution; however, their benefits must be weighed against the reported risks. In a phase 2 trial, a glucagon-like peptide-1 agonist commonly used for diabetes and obesity was found to improve liver histology in patients with NASH. Furthermore, therapeutic agents targeting NASH pathogenesis, including bile acid signaling, insulin resistance, and lipid metabolism, are in various phases of clinical development. In this article, we review the benefits and drawbacks of current pharmacotherapy and the efficacy of upcoming treatments for NASH. |
| first_indexed | 2024-04-10T00:45:27Z |
| format | Article |
| id | doaj.art-cdaa305cfd3d440184849b8c2ecfe771 |
| institution | Directory Open Access Journal |
| issn | 2287-2728 2287-285X |
| language | English |
| last_indexed | 2024-04-10T00:45:27Z |
| publishDate | 2023-02-01 |
| publisher | Korean Association for the Study of the Liver |
| record_format | Article |
| series | Clinical and Molecular Hepatology |
| spelling | doaj.art-cdaa305cfd3d440184849b8c2ecfe7712023-03-14T01:46:51ZengKorean Association for the Study of the LiverClinical and Molecular Hepatology2287-27282287-285X2023-02-0129SupplS268S27510.3350/cmh.2022.04371753Pharmacological advances in the treatment of nonalcoholic fatty liver diseases : focused on global results of randomized controlled trialsJihyun AnJoo Hyun Sohn0 Department of Gastroenterology and Hepatology, Hanyang University College of Medicine, Guri, KoreaNonalcoholic fatty liver disease (NAFLD) is the most common cause of liver disease globally, and its prevalence is rapidly increasing. Nonalcoholic steatohepatitis (NASH), a progressive form of NAFLD, is characterized by hepatocellular injury, inflammation, and fibrosis. Patients with NASH or severe fibrosis should be treated according to international NAFLD guidelines. Currently, regulatory agencies have not approved any pharmaceutical treatment for NAFLD. Vitamin E and pioglitazone are efficacious for NASH resolution; however, their benefits must be weighed against the reported risks. In a phase 2 trial, a glucagon-like peptide-1 agonist commonly used for diabetes and obesity was found to improve liver histology in patients with NASH. Furthermore, therapeutic agents targeting NASH pathogenesis, including bile acid signaling, insulin resistance, and lipid metabolism, are in various phases of clinical development. In this article, we review the benefits and drawbacks of current pharmacotherapy and the efficacy of upcoming treatments for NASH.http://e-cmh.org/upload/pdf/cmh-2022-0437.pdfnonalcoholic fatty liver diseasenonalcoholic steatohepatitistreatmentdrugsclinical trials |
| spellingShingle | Jihyun An Joo Hyun Sohn Pharmacological advances in the treatment of nonalcoholic fatty liver diseases : focused on global results of randomized controlled trials Clinical and Molecular Hepatology nonalcoholic fatty liver disease nonalcoholic steatohepatitis treatment drugs clinical trials |
| title | Pharmacological advances in the treatment of nonalcoholic fatty liver diseases : focused on global results of randomized controlled trials |
| title_full | Pharmacological advances in the treatment of nonalcoholic fatty liver diseases : focused on global results of randomized controlled trials |
| title_fullStr | Pharmacological advances in the treatment of nonalcoholic fatty liver diseases : focused on global results of randomized controlled trials |
| title_full_unstemmed | Pharmacological advances in the treatment of nonalcoholic fatty liver diseases : focused on global results of randomized controlled trials |
| title_short | Pharmacological advances in the treatment of nonalcoholic fatty liver diseases : focused on global results of randomized controlled trials |
| title_sort | pharmacological advances in the treatment of nonalcoholic fatty liver diseases focused on global results of randomized controlled trials |
| topic | nonalcoholic fatty liver disease nonalcoholic steatohepatitis treatment drugs clinical trials |
| url | http://e-cmh.org/upload/pdf/cmh-2022-0437.pdf |
| work_keys_str_mv | AT jihyunan pharmacologicaladvancesinthetreatmentofnonalcoholicfattyliverdiseasesfocusedonglobalresultsofrandomizedcontrolledtrials AT joohyunsohn pharmacologicaladvancesinthetreatmentofnonalcoholicfattyliverdiseasesfocusedonglobalresultsofrandomizedcontrolledtrials |